Merck & Co Inc
MRK
Company Profile
Business description
Merck makes pharmaceutical products to treat several conditions in a number of therapeutic areas, including cardiometabolic disease, cancer, and infections. Within cancer, the firm's immuno-oncology platform is growing as a major contributor to overall sales. The company also has a substantial vaccine business, with treatments to prevent pediatric diseases as well as human papillomavirus, or HPV. Additionally, Merck sells animal health-related drugs. From a geographical perspective, just under half of the company's sales are generated in the United States.
Contact
126 East Lincoln Avenue
RahwayNJ07065
USAT: +1 908 740-4000
Sector
Healthcare
Stock type
Defensive
Industry
Drug Manufacturers - General
Fiscal Year End
31 December 2025
Employees
75,000
Stocks News & Analysis
stocks
The 10 best US dividend stocks
These undervalued stocks with reliable dividends are worth considering.
stocks
10 best US blue-chip stocks to buy for the long term
The stocks of these high-quality companies with large market capitalisations look undervalued today.
stocks
The 10 best US dividend stocks
These undervalued stocks with reliable dividends are worth considering.
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
|---|---|---|---|
| All Ordinaries | 8,812.70 | 70.80 | 0.81% |
| CAC 40 | 7,804.33 | 12.86 | 0.17% |
| DAX 40 | 23,987.56 | 186.76 | -0.77% |
| Dow JONES (US) | 42,866.87 | 105.11 | 0.25% |
| FTSE 100 | 8,853.08 | 20.80 | 0.24% |
| HKSE | 24,162.87 | 18.56 | -0.08% |
| NASDAQ | 19,714.99 | 123.75 | 0.63% |
| Nikkei 225 | 38,211.51 | 122.94 | 0.32% |
| NZX 50 Index | 12,601.01 | 36.59 | 0.29% |
| S&P 500 | 6,038.81 | 32.93 | 0.55% |
| S&P/ASX 200 | 8,587.20 | 71.50 | 0.84% |
| SSE Composite Index | 3,384.82 | 14.96 | -0.44% |